A new in vitro model of the glial scar inhibits axon growth IB Wanner, A Deik, M Torres, A Rosendahl, JT Neary, VP Lemmon, ... Glia 56 (15), 1691-1709, 2008 | 189 | 2008 |
The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease Z Gan-Or, LJ Ozelius, A Bar-Shira, R Saunders-Pullman, A Mirelman, ... Neurology 80 (17), 1606-1610, 2013 | 180 | 2013 |
Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium K Marder, Y Wang, RN Alcalay, H Mejia-Santana, MX Tang, A Lee, ... Neurology 85 (1), 89-95, 2015 | 163 | 2015 |
Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations RN Alcalay, A Mirelman, R Saunders‐Pullman, MX Tang, ... Movement Disorders 28 (14), 1966-1971, 2013 | 138 | 2013 |
Clinical spectrum of stiff person syndrome: a review of recent reports H Sarva, A Deik, A Ullah, WL Severt Tremor and Other Hyperkinetic Movements 6, 2016 | 103 | 2016 |
Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial B Bluett, DM Togasaki, D Mihaila, M Evatt, M Rezak, S Jain, ... Jama 326 (10), 926-939, 2021 | 82 | 2021 |
Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers RC Helmich, A Thaler, BFL Van Nuenen, T Gurevich, A Mirelman, ... Neurology 84 (4), 399-406, 2015 | 80 | 2015 |
Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation A Mirelman, T Heman, K Yasinovsky, A Thaler, T Gurevich, K Marder, ... Movement Disorders 28 (12), 1683-1690, 2013 | 80 | 2013 |
Substance abuse and movement disorders: complex interactions and comorbidities A Deik, R Saunders-Pullman, M San Luciano Current drug abuse reviews 5 (3), 243-253, 2012 | 79 | 2012 |
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers A Thaler, A Mirelman, T Gurevich, E Simon, A Orr-Urtreger, K Marder, ... Neurology 79 (10), 1027-1032, 2012 | 74 | 2012 |
Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance M San Luciano, CM Tanner, C Meng, C Marras, SM Goldman, AE Lang, ... Movement Disorders 35 (10), 1755-1764, 2020 | 70 | 2020 |
Pathophysiology and treatment of alien hand syndrome H Sarva, A Deik, WL Severt Tremor and Other Hyperkinetic Movements 4, 2014 | 62 | 2014 |
Neuropsychiatric characteristics of GBA-associated Parkinson disease M Swan, N Doan, RA Ortega, M Barrett, W Nichols, L Ozelius, ... Journal of the neurological sciences 370, 63-69, 2016 | 57 | 2016 |
A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale, design, and baseline data G Pagano, FG Boess, KI Taylor, B Ricci, B Mollenhauer, W Poewe, ... Frontiers in neurology 12, 705407, 2021 | 52 | 2021 |
Heterogeneity in primary dystonia: Lessons from THAP1, GNAL, and TOR1A in Amish‐Mennonites R Saunders‐Pullman, T Fuchs, M San Luciano, D Raymond, A Brashear, ... Movement Disorders 29 (6), 812-818, 2014 | 44 | 2014 |
Atypical presentation of late‐onset Tay‐sachs disease A Deik, R Saunders‐Pullman Muscle & nerve 49 (5), 768-771, 2014 | 36 | 2014 |
Compound heterozygous PNPLA6 mutations cause Boucher–Neuhäuser syndrome with late-onset ataxia A Deik, B Johannes, JC Rucker, E Sánchez, SE Brodie, E Deegan, ... Journal of neurology 261, 2411-2423, 2014 | 35 | 2014 |
Impact of dyskinesia on activities of daily living in Parkinson's disease: results from pooled phase 3 ADS-5102 clinical trials R Pahwa, S Isaacson, J Jimenez-Shaheed, IA Malaty, A Deik, R Johnson, ... Parkinsonism & related disorders 60, 118-125, 2019 | 32 | 2019 |
Cognitive profile and markers of Alzheimer disease–type pathology in patients with Lewy body dementias E Howard, DJ Irwin, K Rascovsky, N Nevler, S Shellikeri, TF Tropea, ... Neurology 96 (14), e1855-e1864, 2021 | 30 | 2021 |
Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease MJ Barrett, J Hagenah, V Dhawan, S Peng, K Stanley, D Raymond, ... Parkinsonism & related disorders 19 (2), 186-191, 2013 | 29 | 2013 |